ZA202306571B - Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof - Google Patents

Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof

Info

Publication number
ZA202306571B
ZA202306571B ZA2023/06571A ZA202306571A ZA202306571B ZA 202306571 B ZA202306571 B ZA 202306571B ZA 2023/06571 A ZA2023/06571 A ZA 2023/06571A ZA 202306571 A ZA202306571 A ZA 202306571A ZA 202306571 B ZA202306571 B ZA 202306571B
Authority
ZA
South Africa
Prior art keywords
collagen
methods
localized
immunomodulatory molecules
functional linear
Prior art date
Application number
ZA2023/06571A
Other languages
English (en)
Inventor
Naveen Mehta
Jennifer Michaelson
K Dane Wittrup
Patrick Baeuerle
Bochong Li
Original Assignee
Cullinan Amber Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cullinan Amber Corp filed Critical Cullinan Amber Corp
Publication of ZA202306571B publication Critical patent/ZA202306571B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA2023/06571A 2020-12-18 2023-06-26 Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof ZA202306571B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063127995P 2020-12-18 2020-12-18
PCT/US2021/064224 WO2022133326A1 (en) 2020-12-18 2021-12-17 Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof

Publications (1)

Publication Number Publication Date
ZA202306571B true ZA202306571B (en) 2024-11-27

Family

ID=82058332

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/06571A ZA202306571B (en) 2020-12-18 2023-06-26 Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof

Country Status (11)

Country Link
US (1) US20240101630A1 (https=)
EP (1) EP4262840A4 (https=)
JP (1) JP2024500870A (https=)
KR (1) KR20230124633A (https=)
CN (1) CN116887850A (https=)
AU (1) AU2021400761A1 (https=)
CA (1) CA3202397A1 (https=)
IL (1) IL303712A (https=)
MX (1) MX2023007326A (https=)
WO (1) WO2022133326A1 (https=)
ZA (1) ZA202306571B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019346335B2 (en) 2018-09-28 2024-07-25 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
WO2025049528A1 (en) * 2023-08-29 2025-03-06 Cullinan Amber Corp. Combination therapies for cancer
WO2025245169A1 (en) * 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload
WO2025255560A1 (en) * 2024-06-07 2025-12-11 Rush University Medical Center Intranasal p40 monomer and anti-p40 homodimer mab for type 1 diabetes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073661A1 (fr) * 2005-12-26 2007-07-05 Yantai Zhenghai Bio-Technology Co., Ltd. Matieres de squelette de collagene activees et leurs facteurs speciaux de restauration active fusionnee
CA2957717C (en) * 2014-08-12 2021-10-19 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
US12084495B2 (en) * 2016-08-03 2024-09-10 Nextcure, Inc. Compositions and methods for modulating LAIR signal transduction
HUE070957T2 (hu) * 2017-02-16 2025-07-28 Sonnet Biotherapeutics Inc Albuminkötõ domén fúziós fehérjék
AU2019232729B2 (en) * 2018-03-05 2024-08-08 The University Of Chicago Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines
US10786438B2 (en) * 2018-04-27 2020-09-29 Krystal Biotech, Inc. Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
AU2019271148B9 (en) * 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
AU2019335014A1 (en) * 2018-09-05 2021-03-25 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
CA3117961A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
WO2020163264A1 (en) * 2019-02-04 2020-08-13 Neutrolis, Inc. Engineered human extracellular dnase enzymes for drug candidate selection
WO2020186111A2 (en) * 2019-03-12 2020-09-17 xCella Biosciences, Inc. Vista-binding antibodies and uses thereof

Also Published As

Publication number Publication date
KR20230124633A (ko) 2023-08-25
IL303712A (en) 2023-08-01
MX2023007326A (es) 2023-08-22
EP4262840A1 (en) 2023-10-25
CA3202397A1 (en) 2022-06-23
CN116887850A (zh) 2023-10-13
WO2022133326A1 (en) 2022-06-23
AU2021400761A1 (en) 2023-07-06
JP2024500870A (ja) 2024-01-10
US20240101630A1 (en) 2024-03-28
EP4262840A4 (en) 2024-11-20
AU2021400761A9 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
ZA202306571B (en) Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof
MX2021003435A (es) Moleculas inmunomoduladoras localizadas en el colageno y metodos de las mismas.
DK202300015Y9 (da) Ikke-animalsk baserede proteinkilder med funktionelle egenskaber
MX2022003930A (es) Conjugados de péptido de camptotecina.
PH12022551636A1 (en) Anti-cd73 antibodies and uses thereof
PH12021500030A1 (en) Il-2 conjugates and methods of use thereof
MX2023014458A (es) Anticuerpos anti-ccr8 y usos de los mismos.
MX2020010458A (es) Conjugados de camptotecina-peptido.
WO2021173896A8 (en) Materials and methods for modulating an immune response
MXPA05014016A (es) Proteinas portadoras para vacunas.
WO2021181233A3 (en) Cd80-fc fusion protein and uses thereof
WO2021203016A3 (en) Protein-protein interaction stabilizers
WO2020260898A3 (en) Novel cancer antigens and methods
CR20210478A (es) Proteínas de fusión, bacterias recombinantes, y fragmentos de exosporio para el control de plagas y salud vegetal
WO2019241672A3 (en) Glycosylated comp pilin variants, methods of making and uses thereof
ZA202402034B (en) Caix targeting il-12 fusion proteins and methods of use thereof
MX2022014525A (es) Inmunoglobulina hipersialilada.
WO2019009684A3 (ko) 신규 치료학적 효소 융합단백질 및 이의 용도
WO2022099100A3 (en) Binding proteins recognizing ha-1 antigen and uses thereof
WO2023086480A3 (en) Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
WO2021005338A3 (en) Novel cancer antigens and methods
WO2023009529A3 (en) Novel polypeptides and uses thereof
CA3242972A1 (en) Anti-ROR1 antibodies, anti-ROR1 antibody-drug combinations, and their medical uses
MX2025006646A (es) Moleculas de union al antigeno de gp130
WO2020079448A9 (en) Novel cancer antigens and methods